Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial

Steven M Horwitz^{1

2}, Ajit J Nirmal³, Jahan Rahman^#⁴, Ran Xu^#³, Esther Drill⁴, Natasha Galasso⁵, Nivetha Ganesan⁵, Theresa Davey⁵, Helen Hancock⁵, Leslie Perez⁵, Catherine Maccaro⁵, Alexandra Bahgat⁵, Evan Marzouk⁵, Elizabeth Cathcart⁵, Alison Moskowitz⁵, Ariela Noy⁵, Anita Kumar⁵, Eric Jacobsen³, David C Fisher³, Neha Mehta-Shah⁶, Youn H Kim^{7

8}, Michael Khodadoust^{7

8}, Nikita Kotlov⁹, Anastasia Nikitina⁹, Olga Kudryashova⁹, Valeria Zubareva⁹, Ksenia Zornikova⁹, Nara Shin⁹, Maria Sorokina⁹, Sandrine Degryse⁹, Ekaterina Postovalova⁹, Aleksander Bagaev⁹, Kinga Hosszu¹⁰, Devin McAvoy¹⁰, Jaap J Boelens^{10

11}, Wenchao Wu¹², Zoe Ciantra³, Jackson W Appelt³, Christopher Trevisani³, Sam Amaka³, David M Weinstock^{3

13}, Santosha A Vardhana^{14

15

16}

Affiliations

¹ Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. horwitzs@mskcc.org.
² New York Presbyterian Hospital-Weill Cornell Medical College, New York, NY, USA. horwitzs@mskcc.org.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁴ Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁵ Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁶ Department of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
⁷ Division of Oncology, Stanford University, Stanford, CA, USA.
⁸ Department of Dermatology, Stanford University, Stanford, CA, USA.
⁹ BostonGene Corporation, Boston, MA, USA.
¹⁰ Department of Pediatrics and Immune Discovery & Modeling Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹¹ Stem Cell Transplantation and Cellular Therapies, MSK Kids, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹² State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
¹³ Merck and Co., Rahway, NJ, USA.
¹⁴ Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. vardhans@mskcc.org.
¹⁵ New York Presbyterian Hospital-Weill Cornell Medical College, New York, NY, USA. vardhans@mskcc.org.
¹⁶ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. vardhans@mskcc.org.

^# Contributed equally.

PMID: 39548313
DOI: 10.1038/s41591-024-03404-w

Published Erratum

Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial

Steven M Horwitz et al. Nat Med. 2024 Dec.

. 2024 Dec;30(12):3778.

doi: 10.1038/s41591-024-03404-w.

Authors

Affiliations

¹ Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. horwitzs@mskcc.org.
² New York Presbyterian Hospital-Weill Cornell Medical College, New York, NY, USA. horwitzs@mskcc.org.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁴ Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁵ Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁶ Department of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
⁷ Division of Oncology, Stanford University, Stanford, CA, USA.
⁸ Department of Dermatology, Stanford University, Stanford, CA, USA.
⁹ BostonGene Corporation, Boston, MA, USA.
¹⁰ Department of Pediatrics and Immune Discovery & Modeling Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹¹ Stem Cell Transplantation and Cellular Therapies, MSK Kids, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹² State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
¹³ Merck and Co., Rahway, NJ, USA.
¹⁴ Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. vardhans@mskcc.org.
¹⁵ New York Presbyterian Hospital-Weill Cornell Medical College, New York, NY, USA. vardhans@mskcc.org.
¹⁶ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. vardhans@mskcc.org.

^# Contributed equally.

PMID: 39548313
DOI: 10.1038/s41591-024-03404-w

No abstract available

PubMed Disclaimer

Erratum for

Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.
Horwitz SM, Nirmal AJ, Rahman J, Xu R, Drill E, Galasso N, Ganesan N, Davey T, Hancock H, Perez L, Maccaro C, Bahgat A, Marzouk E, Cathcart E, Moskowitz A, Noy A, Kumar A, Jacobsen E, Fisher DC, Mehta-Shah N, Kim YH, Khodadoust M, Kotlov N, Nikitina A, Kudryashova O, Zubareva V, Zornikova K, Shin N, Sorokina M, Degryse S, Postovalova E, Bagaev A, Hosszu K, McAvoy D, Boelens JJ, Wu W, Ciantra Z, Appelt JW, Trevisani C, Amaka S, Weinstock DM, Vardhana SA. Horwitz SM, et al. Nat Med. 2024 Sep;30(9):2517-2527. doi: 10.1038/s41591-024-03076-6. Epub 2024 Jun 17. Nat Med. 2024. PMID: 38886623 Free PMC article. Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial

Affiliations

Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources